Group 1 - The core point of the article is that Jiao Cheng Ultrasonic (688392.SH) has completed a share reduction plan, where Jianlin Management has reduced its holdings by 1.5735% of the company's total share capital, amounting to 1.821 million shares [1] Group 2 - The share reduction was executed through centralized bidding and block trading methods [1] - The reduction plan was fully implemented as of February 6, 2026 [1]

格隆汇2月6日丨山大地纬(688579.SH)公布，公司董事会于近日收到公司现任高级副总裁孙明先生提交 的书面辞职报告。孙明先生因工作调整原因，申请辞去公司高级副总裁职务，孙明先生辞职后将继续担 任公司职工代表董事、工会副主席、信息中心主任，孙明先生递交的辞职报告自送达董事会之日起生 效。 ...

格隆汇2月6日｜罗思资本(ROTH MKM)将亚马逊(AMZN.US)目标价从295美元下调至285美元。 ...

Core Viewpoint - Amazon's commitment to invest $200 billion in capital expenditures by 2026 has overshadowed its cloud business growth of 24% year-over-year, leading to a decline in stock price [1] Group 1: Financial Performance - AWS revenue reached $35.6 billion, exceeding Wall Street's consensus estimate by $700 million [1] - The profit margin for the AWS segment remains robust at 35% [1] Group 2: Market Expectations - Advertising revenue was in line with market expectations, but investors may have anticipated greater upside given previous trends and advancements in Prime Video and Amazon DSP [1]

Core Viewpoint - The Philadelphia Semiconductor Index experienced a significant increase of 4.2%, indicating strong market performance in the semiconductor sector [1]. Group 1: Company Performance - Arm Holdings saw a notable rise of 7.24% [2]. - Marvell Technology and AMD both increased by over 6%, with Marvell at 6.47% and AMD at 6.39% [2]. - Other companies such as Lam Research, KLA, NVIDIA, and Applied Materials also reported gains exceeding 5% [1][2]. Group 2: Additional Company Gains - TSMC (Taiwan Semiconductor Manufacturing Company) rose by 5.02% [2]. - Intel and Broadcom had increases of 4.80% and 4.53%, respectively [2]. - Overall, multiple semiconductor companies demonstrated strong upward momentum, reflecting positive market sentiment [1].

Core Viewpoint - Several shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and investor sentiment in the market [1] Shareholder Reductions - Xuelang Environment's shareholders Yang Jianping and Xu Huifen plan to reduce their holdings by no more than 3% [1] - Dajia Weikang's actual controller's concerted actors also intend to reduce their stakes by no more than 3% [1] - Zhongfutong's shareholders, including Changde Zhongke, Zhejiang Zhongke, and Jinjiang Ronglei, plan to collectively reduce their holdings by no more than 0.68% [1] - Huitong Technology's directors Zhong Ming and Yang Jian plan to reduce their stakes by no more than 1.64% [1] - Shuangjie Electric's director Xu Zhuan intends to reduce his holdings by no more than 378.9 thousand shares [1] - Hu Silicon Industry's shareholder investment fund plans to reduce its holdings by no more than 99.15 million shares [1] - Zhongji United's director and senior vice president Ma Dongsheng plans to reduce his holdings by no more than approximately 110 thousand shares [1] - Lushan New Materials' shareholders Lushan Information and Wang Jiasheng plan to collectively reduce their stakes by no more than 3% [1] - Zhidi Technology's Zhikong Investment plans to reduce its holdings by no more than 24.18 thousand shares [1] - Yinxin Technology's directors and senior management plan to collectively reduce their holdings by no more than 242.7 thousand shares [1] - Huizhi Micro's shareholder Great Fund Phase II plans to reduce its holdings by 0.57542% [1] - Jingda Shares' shareholder Li Guangrong and concerted actors have already collectively reduced their holdings by 64.3 million shares [1] - Huashu High-tech's shareholder Xingwang Construction has reduced its holdings by 236.81 thousand shares [1] Regulatory Actions - Tiansheng New Materials is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure [1] - Yahui Long is also under investigation by the CSRC for suspected violations of information disclosure [1]

Core Viewpoint - Chinese concept stocks collectively strengthened, with the Nasdaq China Golden Dragon Index rising nearly 2% [1] Group 1: Stock Performance - Zenggu and Bomei Group surged over 9% [1] - NIO and New Oxygen increased by more than 8% [1] - Li Auto, Century Internet, Aihuishou, and Hesai rose over 4% [1] - GDS Holdings, Kingsoft Cloud, Baozun, and Huya gained over 3% [1] - Pony.ai, XPeng Motors, Baidu, and Bilibili climbed over 2% [1] - Alibaba, NetEase, and JD.com saw an increase of over 1% [1]

Core Viewpoint - The company, Cuihua Jewelry (002731.SZ), is facing significant financial difficulties due to contract disputes and overdue loans, leading to the freezing of 45 bank accounts and a total frozen amount of 4.72 million RMB [1] Financial Status - As of February 6, 2026, the company and its subsidiaries have overdue principal loans totaling 254 million RMB [1] - Multiple financial institutions have initiated lawsuits or arbitration against the company, resulting in the freezing of major bank accounts [1] Regulatory Impact - The freezing of major bank accounts has triggered a situation that falls under the Shenzhen Stock Exchange's regulations, specifically Article 9.8.1 (6) of the revised 2025 Listing Rules, leading to the implementation of other risk warnings for the company's stock [1] - The company's stock will be suspended for one day starting February 9, 2026, and will resume trading on February 10, 2026, under a new name "ST Cuihua," with a daily price fluctuation limit of 5% [1]

Core Viewpoint - Company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its pharmaceutical product, concentrated solution of racemic norepinephrine for injection, which is intended for the management of severe acute hypotension in adults [1] Group 1 - The product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1] - The approval marks a significant milestone for the company's expansion into the Singapore market [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received the drug registration certificate for Canagliflozin Tablets from the National Medical Products Administration (NMPA) [1] Group 1: Product Approval - The product is indicated for use in adult patients with type 2 diabetes to improve blood sugar control when used in combination with Metformin [1] - It can also be used in conjunction with Metformin and sulfonylureas when blood sugar control is inadequate with these medications alone [1] - The product is not recommended for improving blood sugar control in patients with type 1 diabetes [1]